UNIVERSITE DE GENEVE

Their core work

The University of Geneva is a major Swiss research university with deep strength in neuroscience, brain research, and biomedical sciences. Their H2020 portfolio reveals concentrated expertise in brain imaging, computational neuroscience, and disease biomarkers — particularly for Alzheimer's and other neurological conditions. They also contribute significantly to high-performance computing, particle physics infrastructure, and climate/environmental observation. With over EUR 116M in EU funding across 203 projects, they function as both a scientific powerhouse and a reliable consortium partner for large-scale European research initiatives.

What they specialise in

How they've shifted over time

In the early period (2015–2018), Geneva's work was anchored in computational neuroscience — brain imaging, simulation, neuroinformatics, neuromorphic computing, and Alzheimer's/dementia research dominated their portfolio. The later period (2019–2022) shows a clear pivot toward data-driven biomedical research: machine learning, organoids, synaptic plasticity, and personalized medicine emerged as new focus areas, while neuroscience remained a throughline. This evolution reflects a broader shift from descriptive brain mapping toward predictive, AI-powered medicine.

Geneva is increasingly combining its neuroscience heritage with machine learning and clinical biomarkers, positioning itself as a prime partner for AI-in-health and precision medicine consortia.

How they like to work

With 73 coordinated projects out of 203 (36%), Geneva is an unusually active consortium leader for a university — most coordinate far fewer. Their 1,409 unique partners across 60 countries indicate a hub-style network rather than a closed circle of repeat collaborators. They are comfortable leading large RIA consortia but also attract significant individual researcher funding (22 MSCA fellowships, 13 ERC Starting Grants), showing strength at both institutional and PI levels.

With 1,409 unique consortium partners spanning 60 countries, Geneva operates one of the broadest collaboration networks in European research. As a Swiss institution, they bridge EU and non-EU research ecosystems, with partnerships reaching well beyond Europe into global networks.

What sets them apart

Geneva combines world-class neuroscience with strong computational infrastructure and an unusually high coordination rate, making them a natural consortium lead for brain-related and health-data projects. As a Swiss institution participating at this scale in H2020, they offer access to Switzerland's research ecosystem — CERN proximity, Swiss precision medicine initiatives, and federal research funding — while maintaining deep integration with European networks. Their breadth across 10+ sectors and 60 countries means they can assemble diverse consortia quickly.

Highlights from their portfolio

• ECOPOTENTIAL
  Large-scale ecosystem observation project combining Earth observation with ecosystem modelling across European protected areas
• CoSTREAM
  Six-year project (2015–2021) investigating shared mechanisms between stroke and Alzheimer's — reflects Geneva's core neuroscience-meets-biomarkers strength
• MEDIT-AGEING
  Ambitious six-year project (2016–2022) studying meditation's impact on ageing and dementia, combining neuroimaging, biomarkers, and lifestyle interventions